MultiCell Technologies Inc (MCET)

[OCKHAM'S RAZOR]

MCET DRUG PIPELINE:

http://www.multicelltech.com/Therapeutic-Pipeline

They also own:

http://xenogenicscorp.com

I am shocked this is not a BUYOUT TAKEOVER from BIG PHARMA


MCET has/had license revenue agreements with Corning, Pfizer and Eisai

CANCER ASPECT:

http://www.multicelltech.com/Discovery-Platform-and-Disease-Targets/Cancer

http://www.multicelltech.com/Discovery-Platform-and-Disease-Targets/Primary-MS-Related-Fatigue

MultiCell operates three subsidiaries, which include MCT Rhode Island Corp. (wholly owned); Xenogenics Corporation (Xenogenics) (95.3% owned, on an as-if-convertd basis), and MultiCell Immunotherapeutics, Inc. (MCTI), of which MultiCell holds approximately 67% of interests. As of November 30, 2011, the Company’s portfolio of drug candidates, which were in various stages of discovery optimization, and preclinical and clinical development included MCT-125, MCT-465, MCT-475 and MCT-485.

The Company’s MCT-485 is a discovery stage double-stranded ribonucleic acid (dsRNA) therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers. MCT-465, a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing Toll-like receptor (TLR-3). MCT-475, a discovery stage antibody therapeutic candidate used in combination with dsRNA for the treatment of solid tumor cancers.

MultiCell’s therapeutics business addresses unmet medical needs for the treatment of neurological disorders and cancer through modulation of the innate and adaptive immune response. Its therapeutic development platform includes several techniques used to isolate, characterize and differentiate stem cells from human liver; control the immune response at transcriptional and translational levels through dsRNA-sensing molecules, such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling; generate specific and potent immunity against key tumor targets through an immunoglobulin platform technology; modulate the noradrenaline-adrenaline neurotransmitter pathway, and the design of next-generation bioabsorbable stents, the Ideal BioStent, for interventional cardiology and peripheral vessel applications.


The Company’s Ideal BioStent is a stent incorporating salicylate, the active component in aspirin, directly into the polymer chain. The Ideal BioStent also incorporates Sirolimus (rapamycin) in addition to salicylate into the Ideal BioStent, providing anti-restenotic therapy similar to drug-eluting metal stents.



MCT-125 for the treatment of fatigue in patients with multiple sclerosis
MCT-125 is a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue (PMSF), which has demonstrated efficacy in a 138 patient Phase IIa clinical trial. MultiCell focuses to proceed with the anticipated pivotal Phase IIb/III trial of MCT-125 using the data generated by Amarin for LAX-202.

MCT-465 and MCT-475 for the treatment of cancer
MCT-465 is a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers, such as those expressing Toll-like Receptor 3 (TLR-3). MCT-475 is a discovery stage antibody therapeutic candidate used in combination with dsRNA for the treatment of solid tumor cancers. MCT-465, MCT-475 and MCT-485 are a family of prospective cancer therapeutics based on the use of its TLR3 signaling (MCT-465 and MCT-485) and Ig-peptide construct (MCT-475) technology. MCT-465, MCT-475, and MCT 485 are in preclinical development, and are being investigated as prospective treatments for primary liver cancer and triple negative breast cancer.

The Rhode Island-based biopharmaceutical firm has signed an agreement with Rhode Island Hospital to be the worldwide licensee of U.S. patent 7,935,528.

http://www.insidermonkey.com/insider-trading/purchases/